Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.75
Bid: 0.70
Ask: 0.80
Change: 0.00 (0.00%)
Spread: 0.10 (14.286%)
Open: 0.75
High: 0.75
Low: 0.75
Prev. Close: 0.75
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS SUMMARY: Franchise Brands blooms; Tlou Energy loss widens

Thu, 09th Mar 2023 14:32

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Franchise Brands PLC - Manchester-based owner of ChipsAway, Willow Pumps and Metro Rod brands - Pretax profit in 2022 jumps 78% to GBP10.3 million from GBP5.8 million in 2021, boosted by business to business division. Revenue grows 72% to GBP99.2 million from GBP57.7 million. Proposes final dividend of 1.1 pence per share, up from 0.9p a year ago. Total dividend is 2.0p per share, up 33% from 1.5p. Net cash as at December 31 grows to GBP8.0 million from GBP6.5 million. Executive Chair Stephen Hemsley says: "The excellent momentum in the B2B businesses has continued in 2023 to date, as we capture the defensive growth opportunities afforded by the group's mostly essential services, strong leadership positions in its chosen markets, and reputation for high quality, reliable services among its diversified client base. We look forward with confidence to expanding the business organically and by seeking further earnings-enhancing acquisitions."

----------

Hansard Global PLC - Isle of Man-based long-term savings provider - In six months to December 31, pretax profit grows to GBP3.1 million from GBP1.9 million a year prior. Maintains interim dividend of 1.8p per share. Net asset value per share as at December 31 falls to 15.6p from 16.7p a year ago. Anticipates sales of long-term savings products to continue to be impacted by global economic headwinds, but adds: "however, we are confident that our new product pipeline will lead to increased sales and long term growth in the business."

----------

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - In 2022, pretax loss narrows to GBP1.2 million from GBP1.8 million in 2021. Research & development costs reduce to GBP577,525 from GBP1.2 million. Company does not make revenue in 2022 or 2021. Notes delays of research grade materials due to global shortages. Says work is underway, with full results expected by the end of the second quarter of 2023.

----------

Seraphim Space Investment Trust PLC - London-based space technology investment company - Net asset value per share as at December 31 declines 7.2% to 92.74 pence per share from 99.97p at June 30. Company does not expect to recommend payouts in the near future due to its focus on achieving capital growth. In its outlook, notes innovation of Western economies regarding the impact of Russia's war in Ukraine. Chair Will Whitehorn says: "The investment manager is actively engaged with numerous investment prospects, carefully selecting those with a strong growth premise and offer the highest returns for shareholders. It is taking a cautious approach to the allocation of cash between supporting existing portfolio companies, making new investments, and managing the company's working capital until the market improves and more capital can be raised."

----------

Tlou Energy Ltd - Brisbane, Australia-based power project developer with large gas field in Botswana - In the six months to December 31, pretax loss widens to AUD2.2 million from AUD1.3 million a year ago. Employee benefits expense increases to AUD564,644 from AUD320,901. Posts an interest expense of AUD296,013 compared to none a year ago. Expenses classified as other widen to AUD1.0m million from AUD585,650. Expects work on purpose-built operations facility for 10 megawatt development at Lesedi, Botswana to be completed during 2023, with potential annual generation of about USD10 million in revenue from the project.

----------

Town Centre Securities PLC - Leeds, England based property investment and car parking operator - Net asset value as at December 31 is virtually flat at 314 pence per share, compared to 313p a year ago. It is down 7.9% from 341p at June 30, 2022. Maintains interim dividend at 2.5p per share. EPRA net tangible assets per share as at June 30 falls to 306p from 333p a year ago. Looking ahead, says that trading performance seen in the first half of financial year 2023 is performing into the opening months of calendar year 2023, with rent collections robust at 99% of amounts invoiced at the last quarter now collected. "The momentum in our car parks recovery has continued through 2022 however for those car parks that are particularly reliant on office workers, this recovery remains slow," it adds.

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
9 Jul 2018 08:40

N4 Pharma Shares Fall As Sildenafil Trial Falls Short Of Expectations

LONDON (Alliance News) - Shares in N4 Pharma PLC plunged early Monday as the company said that its sildenafil reformulation clinical trial has not met its key target endpoints.Shares in the

Read more
18 Jun 2018 11:54

N4 Pharma Says Team Making Progress In Nuvec Manufacturing Process

LONDON (Alliance News) - Drug reformulator N4 Pharma PLC said Monday work to develop a manufacturing process for Nuvec has begun "well" with the team making progress.Nuvec is a to

Read more
9 May 2018 14:13

N4 Pharma Files Patent For Drug To Treat Premature Ejaculation

LONDON (Alliance News) - Pharmaceutical company N4 Pharma PLC announced on Wednesday it has filed a patent application for a treatment for premature ejaculation.N4 Pharm's drug is an of

Read more
25 Apr 2018 11:54

N4 Pharma Outlook Optimistic But Loss Widens After Reverse Takeover

LONDON (Alliance News) - N4 Pharma PLC on Wednesday said it remains optimistic for future as progresses its drug and vaccine development, but the company's loss widened in 2017 following its a

Read more
18 Apr 2018 12:15

N4 Pharma Starts Clinical Trial Of Reformulated Sildenafil

LONDON (Alliance News) - N4 Pharma PLC said Wednesday that it has commenced proof of concept clinical trial for erectile dysfunction treatment drug sildenafil, following the completion of the of a

Read more
9 Mar 2018 10:43

N4 Pharma Raises Nets GBP159,700 From Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Friday it issued 1.9 million shares due to exercise of warrants, raising GBP159,700 for the pharmaceutical warrants

Read more
8 Mar 2018 13:34

N4 Pharma Unveils Two-Pronged Strategy For Nuvec Development

LONDON (Alliance News) - N4 Pharma PLC announced Thursday a two-fold development strategy for its Nuvec technology, as well as a new head of development for Nuvec.Nuvec

Read more
7 Mar 2018 12:41

N4 Pharma Raises Further GBP30,451 After Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Wednesday it issued 358,245 shares due to exercise of warrants, raising GBP30,451 for the pharmaceutical warrants at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.